TraceLink Adds Industry Visionaries to Discuss Machine Learning, Artificial Intelligence, Big Data and Patient Engagement at FutureLink Munich

TraceLink Adds Industry Visionaries to Discuss Machine Learning, Artificial Intelligence, Big Data and Patient Engagement at FutureLink Munich

PR Newswire

NORTH READING, Massachusetts, May 14, 2018

NORTH READING, Massachusetts, May 14, 2018 /PRNewswire/ -- TraceLink Inc., the World's Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced the latest keynote speakers for its upcoming FutureLink Munich conference to be held June 5-7, 2018.  Confirmed speakers include industry and academic thought-leaders: Professor Elgar Fleisch, Ph.D., of ETH Zurich; Justus Wolff of the Syte Institute; and, Andrew Rut, M.D., CEO, MyMeds&Me.

FutureLink Munich Addresses Artificial Intelligence, Machine Learning and Patient Engagement
The unique FutureLink value track will address the operational and commercial challenges in the pharmaceutical and healthcare arenas, delivering industry insights on how to capitalize on serialization and big data with artificial intelligence (AI), machine learning and predictive analytics, to improve patient outcomes. The conference will include discussions and workshops for commercial executives interested developing transformative strategies for brand protection, patient safety, instant and accurate product recalls and directly engaging healthcare providers at the point-of-dispense, and with patients at the point of consumption.

Featured value speakers at FutureLink Munich include:

"The future of healthcare is heading towards this revolutionarymerge of the digital and physical world. New and advanced technologies such as high-resolution sensors, machine learning, digital biomarkers, health data platforms and conversational agents, will transform global healthcare in fighting chronic illnesses such as cardiovascular disease, cancer, chronic respiratory disease, diabetes, and mental illness," said Professor Fleisch. "To a large part, these diseases can be prevented or relieved by inducing behavioral change and leveraging AI and precision medicine. For the first time, through these technological advancements, as well as the ability to seamlessly share information, such as serialized data, we have the scalable platforms to make a positive impact on alleviating the burden of these diseases."

"I am delighted to be speaking at FutureLink, which will provide an opportunity to delve into challenges across the global pharmaceutical supply chain. The event will address highly topical issues including real-time information sharing for increased patient safety," said Dr. Rut, CEO of MyMeds&Me. "The move towards pharmaceutical serialisation is imminent and, as a result, EU FMD requirements, such as medicine verification both at the pharmacy level and in future directly by consumers, enables accurate and immediate linkage of adverse events with potential product quality issues. The goal is to detect quality and safety issues early and provide patients and healthcare professionals the assurance of product integrity."

FutureLink Munich is being held at the Sheraton Munich Arabellapark Hotel. For further information and to register for the conference, visit https://www.tracelink.com/futurelink-munich/about.

About TraceLink
TraceLink is the World's Largest Track and Trace Network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace. Leading businesses trust the TraceLink Life Sciences Cloud to deliver complete global connectivity, visibility and traceability of pharmaceuticals from ingredient to patient. A single point and click connection to the Life Sciences Cloud creates a supply chain control tower that delivers the information, insight and collaboration needed to improve performance and reduce risk across global supply, manufacturing and distribution operations. A winner of numerous industry awards including Deloitte's Technology Fast 500 (ranked number 149 in 2016), the Amazon AWS Global Start-Up Challenge Grand Prize, and the Edison Award for Innovation in Health Management, the Life Sciences Cloud is used by businesses across the globe to meet strategic goals in ensuring global compliance, fighting drug counterfeiting, improving on-time and in-full delivery, protecting product quality and reducing operational cost. For more information on TraceLink and our solutions, visit www.tracelink.com or follow us on LinkedIn, Twitter and Facebook.

TraceLink is funded by Goldman Sachs, FirstMark Capital, Volition Capital and F-Prime Capital.

Logo- https://mma.prnewswire.com/media/690309/TraceLink_Logo.jpg

Voltar noticias em Inglês